EUVIMEDEUVIMED entdecken
Crossref

Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics

Dongli Qi, Bei Jia, Hui Peng, Jiachen He, Jiaxin Pi, Pan Guo, Ying Zhang, Xiuping Deng, Jiawei Li, Zhidong Liu

European Journal of Pharmaceutics and Biopharmaceutics · 2023

DOI: 10.1016/j.ejpb.2023.05.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2023. Verfasst von Dongli Qi und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Engineering Rese…. Hauptthemen laut MEDLINE: Ambroxol, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Tianjin Science and Technology Program, State Administration of Traditional Chinese Medicine of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal lung disease caused by multiple factors. Currently, safe, and effective drugs for the treatment of IPF have been extremely scarce. Baicalin (BA) is used to treat pulmonary fibrosis, IPF, chronic obstructive pulmonary disease, and other lung diseases. Ambroxol hydrochloride (AH), a respiratory tract lubricant and expectorant, is often used to treat chronic respiratory diseases, such as bronchial asthma, emphysema, tuberculosis, and cough. The combination of BA and AH can relieve cough and phlegm, improve lung function, and potentially treat IPF and its symptoms. However, given the extremely low solubility of BA, its bioavailability for oral absorptions is also low. AH, on the other hand, has been associated with certain side effects, such as gastrointestinal tract and acute allergic reactions, which limit its applicability. Therefore, an efficient drug delivery system is urgently needed to address the mentioned problems. This study combined BA and AH as model drugs with L-leucine (L-leu) as the excipient to prepare BA/AH dry powder inhalations (BA/AH DPIs) using the co-spray drying method. We the performed modern pharmaceutical evaluation, which includes particle size, differential scanning calorimetry analysis, X-ray diffraction, scanning electron microscope, hygroscopicity, in vitro aerodynamic analysis, pharmacokinetics, and pharmacodynamics. Notably, BA/AH DPIs were found to be advantageous over BA and AH in treating IPF and had better efficacy in improving lung function than did the positive drug pirfenidone. The BA/AH DPI is a promising preparation for the treatment of IPF given its lung targeting, rapid efficacy, and high lung bioavailability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmbroxolIdiopathic Pulmonary FibrosisHumansPowdersCoughRespiratory Aerosols and DropletsAdministration, InhalationLungDry Powder InhalersParticle SizeFlavonoids

Stichwörter der Autor:innen

Ambroxol hydrochlorideBaicalinDry powder inhalationIdiopathic pulmonary fibrosisLung targetingPharmacokinetic analysisPulmonary administration

Substanzen

AmbroxolPowdersbaicalinFlavonoids

Autor:innen und Institutionen

  • State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Techn…
  • College of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300617, China.

Förderung

  • Tianjin Science and Technology Program
  • State Administration of Traditional Chinese Medicine of the People's Republic of China

Zitieren

APA

Qi, D., Jia, B., Peng, H., He, J., Pi, J., Guo, P., Zhang, Y., Deng, X., Li, J., & Liu, Z. (2023). Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2023.05.017

Vancouver

Qi D, Jia B, Peng H, He J, Pi J, Guo P, et al. Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics. European Journal of Pharmaceutics and Biopharmaceutics. 2023. doi:10.1016/j.ejpb.2023.05.017

BibTeX
@article{Qi2023,
  author = {Qi, Dongli and Jia, Bei and Peng, Hui and He, Jiachen and Pi, Jiaxin and Guo, Pan and Zhang, Ying and Deng, Xiuping and Li, Jiawei and Liu, Zhidong},
  title = {Baicalin/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2023},
  doi = {10.1016/j.ejpb.2023.05.017}
}
Kostenlos starten →